Learn to develop real medical devices from concept through post-market surveillance — device classification and regulatory strategy, ISO 13485 quality systems, ISO 14971 risk management, biomaterials, biomechanics, biosignal processing, medical imaging, sterilization, human factors, software as a medical device, clinical trials, and the applied domains of cardiac devices, neural devices, prosthetics, and drug delivery. 20 modules from fundamentals through capstone, 5 complete real-project deliverables (device risk file, 510(k) predicate comparison, implantable battery sizing, biosignal amplifier front end, sterilization validation protocol), and a certificate of completion. One-time $4.99 purchase, no account required.
Explore the Full Curriculum →No — unlike civil or structural engineering, most biomedical engineering roles (device design, R&D, clinical engineering) do not legally require a PE stamp. Some biomedical engineers still pursue FE/PE licensure, particularly those in consulting or roles that require stamping engineering documents, but it is far less universal in this field than in civil/structural practice.
A biomedical engineer typically designs, develops, and validates medical devices (often requiring a 4-year engineering degree), while a BMET installs, maintains, tests, and repairs medical equipment already in clinical use in hospitals and healthcare facilities — a role most commonly credentialed by the CBET certification rather than a 4-year engineering degree, though there is overlap and some engineers do BMET-type work.
No. The RAC is a professional certification administered by RAPS (Regulatory Affairs Professionals Society) that requires eligibility criteria and a proctored exam. This studio's ISO 13485 & Regulatory Affairs Fundamentals exam is a free, in-house practice set covering the same core FDA/ISO concepts as a study primer — it is not affiliated with or a substitute for RAC certification.
Yes. CBET certification requires periodic recertification through the AAMI Credentials Institute, typically via continuing education points or exam retake — always verify the current recertification cycle and requirements directly with the AAMI Credentials Institute.
Why one Class II wound dressing reaches market in months by pointing at a predecessor device, while a Class III heart valve needs years of original clinical evidence — the same FDA, two structurally different burdens of proof.
Both carry real patient risk, so why does only one require general-and-special controls while the other needs full Premarket Approval? The dividing line is whether the device sustains or supports life — not simply how invasive it looks.
One is a room-temperature gas that leaves a toxic residue requiring days of aeration. The other is ionizing radiation that leaves no residue at all but can quietly embrittle the wrong polymer. Neither is simply “better” — the device's own materials decide which one is even possible.
A material can provoke zero immune reaction and still corrode apart inside the body — or resist degradation for decades while quietly triggering chronic inflammation. Two independent properties, routinely confused as one.
Both are surface biopotential recordings built on the same instrumentation-amplifier front end — so why does EEG demand roughly 100x lower input-referred noise than ECG to even see its own signal?
A hip implant and a pacemaker are both permanently implanted, life-touching devices — but only one has a battery, firmware, and an end-of-service-life problem the other structurally cannot have.
One delivers on a fixed, pre-programmed schedule regardless of the body's actual state. The other senses a physiological signal and adjusts dosing in real time — a difference that turns an insulin pump into an artificial pancreas.
“We built it right” and “we built the right thing” sound like the same sentence — in a Design History File they are two separate, independently required proofs, and passing one says nothing about the other.
A transdermal patch engineered for a steady, constant release rate behaves nothing like a simple diffusion-driven reservoir that dumps its dose fast and tapers off — same drug, same device category, opposite concentration-over-time curve.